STOCK TITAN

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

IceCure Medical (ICCM) reported 83% year-over-year U.S. sales growth for ProSense and its cryoprobes in the nine months ended September 30, 2026. Total revenue rose approximately 26% to $2.642 million, and gross profit rose to $762,000 from $626,000. Net loss widened to $12.995 million from $10.811 million, and operating cash use rose to $12.575 million from $9.555 million. Cash and equivalents stood at $8.220 million at September 30.

U.S. commercial reach expanded to 21 states in Q3 2026 from 11 in Q3 2025. IceCure received Chinese marketing approval for ProSense and signed an exclusive distribution agreement in the Netherlands. The ChoICE study of tumor freezing for low-risk breast cancer opened its first sites in Q3. After quarter-end, three more sites joined, the first two patients enrolled, and the first treatment was completed.

Loading...
Loading translation...
13 points · 2 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

3 major · 14 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointNet proceeds from shares, warrants and pre-funded warrants totaled $12.020 million through September 2026 4.2× market cap
  • Major pointChina marketing approval permits IceCure to market ProSense as a Class III medical device
  • Moderate pointU.S. ProSense and cryoprobe sales rose 83% year over year in the first nine months of 2026
  • Moderate pointTotal revenue rose approximately 26% to $2.642 million from $2.100 million year over year through September
  • Moderate pointU.S. commercial reach expanded to 21 states in Q3 2026 from 11 in Q3 2025
  • Moderate pointExclusive Netherlands distribution agreement signed for ProSense systems
7 minor points
  • Minor pointGross profit rose approximately 22% to $762,000 from $626,000 year over year through September
  • Minor pointBasic and diluted net loss per share narrowed to $3.57 from $5.40 year over year through September
  • Minor pointFirst ChoICE treatment was completed after quarter-end at West Cancer Center in Germantown, Tennessee
  • Minor pointFirst two ChoICE patients enrolled after quarter-end at two U.S. clinical sites
  • Minor pointChoICE site expansion began with the first sites opening in Q3; three more joined after quarter-end
  • Minor pointU.S. commercial team added sales, marketing and clinical support staff in Q3 2026
  • Minor pointWarrant and pre-funded warrant exercises provided $10,000 through September 2026

Negative

  • Major pointNet loss widened to $12.995 million from $10.811 million year over year through September
  • Major pointOperating cash use rose to $12.575 million from $9.555 million year over year through September
  • Major pointOrdinary shares outstanding rose to 5,563,265 at September 30, 2026, from 2,437,410 at December 31, 2025
  • Minor pointOperating loss widened to $12.991 million from $10.878 million year over year through September
  • Minor point. Forward-looking: it has not happened yet and may not happen.Warrants and pre-funded warrants issued can dilute existing holders when exercised
9 minor points
  • Minor pointResearch and development expenses rose to $6.557 million from $5.137 million year over year through September
  • Minor pointCash and cash equivalents fell to $8.220 million at September 30, 2026, from $8.897 million at December 31, 2025
  • Minor pointSales and marketing expenses rose to $3.669 million from $3.061 million year over year through September
  • Minor pointCost of revenue rose to $1.880 million from $1.474 million year over year through September
  • Minor pointLong-term lease liabilities rose to $452,000 at September 30, 2026, from $13,000 at December 31, 2025
  • Minor pointShareholders’ equity fell to $8.774 million at September 30, 2026, from $9.051 million at December 31, 2025
  • Minor pointGeneral and administrative expenses rose to $3.527 million from $3.306 million year over year through September
  • Minor pointProperty and equipment purchases rose to $154,000 from $31,000 year over year through September
  • Minor pointNet finance expense was $4,000, compared with $67,000 in net finance income a year earlier through September

News Explained

Net issuance proceeds were 12,020 thousand dollars, against operating cash use of 12,575 thousand dollars for the nine months.

In reporting results for the nine months ended September 30, 2026, IceCure disclosed that ordinary shares outstanding rose from 2,437,410 at December 31, 2025 to 5,563,265 at September 30, 2026, reducing existing holders’ percentage ownership absent offsetting changes.

For the same nine-month period, the company reported net proceeds of $12,020 thousand from issuing ordinary shares, warrants and pre-funded warrants, compared with $12,575 thousand used in operating activities.

Key Figures

Revenue: Approximately $2.6 million; up approximately 26% U.S. sales growth: 83% year over year U.S. commercial reach: 21 states +4 more
Revenue
Approximately $2.6 million; up approximately 26%
Nine months ended September 30, 2026; $2.1 million in the corresponding 2025 period
U.S. sales growth
83% year over year
First nine months of 2026
U.S. commercial reach
21 states
Third quarter of 2026; 11 states in the third quarter of 2025
Gross profit
$762,000; increased approximately 22%
Nine months ended September 30, 2026; $626,000 in the corresponding 2025 period
Research and development expenses
$6.5 million
Nine months ended September 30, 2026; $5.1 million in the corresponding 2025 period
Net loss
$12.9 million
Nine months ended September 30, 2026; $10.8 million in the corresponding 2025 period
Cash and cash equivalents
Approximately $8.2 million
As of September 30, 2026

Previous Earnings Reports

2 past events · Latest: Aug 12
Same Type 2 events
  1. Aug 12

    First-half earnings

    24h Move
    -11.5%

    First-half revenue rose 45% as net loss widened amid increased commercial and study spending.

  2. Nov 19

    Nine-month earnings

    24h Move
    -3.2%

    Comparable nine-month results established $2.1 million revenue and $10.8 million net loss.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cryoablation, institutional review board, class iii medical device, adjuvant endocrine therapy
4 terms
cryoablation medical
"evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer"
A medical treatment that uses extreme cold to freeze and destroy unwanted tissue, such as small tumors or heart tissue causing irregular rhythms; think of it like applying a focused freezer to stop a problem spot without cutting it out. It matters to investors because devices, tools, and drugs tied to cryoablation, plus clinical results, approval status and insurance coverage, can drive sales, shape market adoption and affect the financial outlook of healthcare companies.
institutional review board medical
"after Institutional Review Board ("IRB") approval"
An institutional review board is an independent committee that reviews and approves research involving people to make sure studies are safe, ethical, and protect participants’ rights and privacy. For investors, IRB approval is a gatekeeper: it can determine whether a clinical trial can start or continue, affecting timelines, regulatory risk, cost and the credibility of trial results—similar to a safety inspector whose sign-off is required before work can proceed.
class iii medical device regulatory
"to market ProSense® as a Class III medical device"
A class III medical device is a regulatory category for devices that support or sustain human life, are implanted, or present a potential high risk to patients; examples include heart valves and implantable neurostimulators. Regulators require the most rigorous review—typically premarket approval with clinical evidence—to show safety and effectiveness before sale. For investors, the label signals longer, more expensive approval pathways and greater regulatory scrutiny, which can affect development timelines, costs, and commercial risk.
adjuvant endocrine therapy medical
"who are treated with adjuvant endocrine therapy"
A course of hormone-blocking medication given after initial cancer treatment (surgery, radiation or chemotherapy) to lower the chance the tumor will return in cancers that grow in response to hormones such as estrogen or progesterone. It matters to investors because these therapies are taken long-term like an insurance policy against recurrence, so changes in guidelines, patent status, or safety data can materially affect drug sales, market size and reimbursement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.

IceCure Medical Logo

Third Quarter 2026 Operational and Clinical Highlights

  • 83% Growth in U.S. Sales: U.S. sales of ProSense® and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025.
  • 26% Year-Over-Year Revenue Growth: Total revenues for the first nine months of 2026 increased to approximately $2.6 million, compared to $2.1 million in the corresponding period of 2025.
  • Expanded U.S. Commercial Reach: The Company's commercial presence expanded from 11 states in the third quarter of 2025 to 21 states in the third quarter of 2026.
  • Continued Progress in the ChoICE Study: The Company's post-marketing study (the "ChoICE" Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer launched the first clinical sites after Institutional Review Board ("IRB") approval at West Cancer Center & Research Institute (the "West Cancer Center") in Germantown, TN and Adventist Health Glendale in Glendale, CA.
  • International Commercial and Regulatory Progress: Received regulatory approval from China's National Medical Products Administration to market ProSense® as a Class III medical device and signed an exclusive distribution agreement for ProSense® cryoablation systems in the Netherlands.

"We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®," said Eyal Shamir, Chief Executive Officer of IceCure Medical.

ChoICE Study Moving Forward:

Subsequent to the end of the third quarter of 2026, IceCure announced additional progress in its ChoICE Study:

  • Three clinical sites joined the Company's study, including Legacy Health in Portland, Oregon.
  • The Company announced the enrollment of the first two patients in the ChoICE Study at two U.S. clinical sites: West Cancer Center in Tennessee and Adventist Health Glendale in California.
  • The Company announced the successful completion of the first ProSense® cryoablation treatment in the ChoICE Study. The first patient was treated at West Cancer Center in Germantown, Tennessee, by Dr. Richard E. Fine, MD, FACS.

Additional Third Quarter of 2026 Successes:

  • Expanded U.S. Commercial Team: Strengthened the U.S. sales and marketing organization by adding dedicated professionals in key territories, including New York, Southern California and the Midwest, and Florida, as well as additional clinical support personnel to support physician training and adoption of ProSense®.
  • Participation in Leading Medical Events: Participated in key medical and industry events, including Aptitude Health's Targeted Medical Education ("TME") Take the Lead in Breast Cancer Fall Summit 2026 in New Orleans, LA and the 2026 European Society of Breast Imaging ("EUSOBI") Congress in Maastricht, Netherlands, engaging with leading breast cancer specialists and the broader medical community.
  • Strengthened Clinical Evidence: Highlighted two new peer-reviewed scientific publications supporting the role of cryoablation in breast cancer treatment de-escalation, including publications addressing early-stage breast cancer and axillary lymph node metastases.
  • Professional Recognition of Cryoablation: The Society of Interventional Oncology ("SIO") submitted a formal petition to the National Comprehensive Cancer Network ("NCCN") to include percutaneous cryoablation as a treatment option in its breast cancer guidelines, potentially broadening the range of treatment options available to eligible patients.

Financial Results for the Nine Months Ended September 30, 2026

Total revenues for the nine months ended September 30, 2026 increased approximately 26% to $2.6 million, compared to $2.1 million for the corresponding period in 2025.

Gross profit for the nine months ended September 30, 2026 increased approximately 22% to $762,000, compared to $626,000 in the corresponding period of 2025.

Research and development expenses for the nine months ended September 30, 2026 were $6.5 million, compared to $5.1 million in the corresponding period of 2025, primarily reflecting increased expenses related to the ChoICE Study and other clinical and development activities.

Sales and marketing expenses were $3.6 million for the nine months ended September 30, 2026, compared to $3.0 million in the corresponding period of 2025, primarily reflecting the continued expansion of the Company's U.S. commercial activities.

General and administrative expenses were $3.5 million for the nine months ended September 30, 2026, compared to $3.3 million in the corresponding period of 2025.

Operating loss for the nine months ended September 30, 2026 was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

Net loss for the nine months ended September 30, 2026, was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

As of September 30, 2026, the Company's cash and cash equivalents totaled approximately $8.2 million, and shareholders' equity was approximately $8.7 million.

Conference call & webcast info: 

Wednesday, November 18, 2026, at 10:00 am EST
US: 1-888-407-2553
Israel/International: +972-3-918-0696
A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
A recording of the webcast will be available at: https://ir.icecure-medical.com/

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company's developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Relations:

Meir Peleg, CFO

investors@icecure-medical.com

+1-888-902-5716

 

ICECURE MEDICAL LTD.


CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION






As of
September 30,
2026



As of
December 31,
2025




(Unaudited)







U.S. dollars in thousands









ASSETS







CURRENT ASSETS







     Cash and cash equivalents



8,220




8,897


     Trade receivables



391




331


     Inventory



2,578




2,625


     Prepaid expenses and other receivables



1,298




752


Total current assets



12,487




12,605











NON-CURRENT ASSETS









     Right-of-use assets



729




239


     Property and equipment, net



940




993


     Long-term restricted deposits



53




51


Total non-current assets



1,722




1,283


TOTAL ASSETS



14,209




13,888











LIABILITIES AND SHAREHOLDERS' EQUITY


















CURRENT LIABILITIES









     Trade payables



1,071




863


     Lease liabilities



255




204


     Employees and employees related benefits



3,024




2,659


     Other current liabilities



633




1,098


Total current liabilities



4,983




4,824











NON-CURRENT LIABILITIES









     Long-term lease liabilities



452




13


Total non-current liabilities



452




13











SHAREHOLDERS' EQUITY









Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and
outstanding: 5,563,265 shares and 2,437,410 shares as of September 30,
2026 and December 31, 2025, respectively









     Additional paid-in capital



142,205




129,487


     Accumulated deficit



(133,431)




(120,436)


     Total shareholders' equity



8,774




9,051


     TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY



14,209




13,888


 

ICECURE MEDICAL LTD.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS






Nine months ended
September 30,




2026



2025




U.S. dollars in thousands
(except per share data)


Revenues



2,642




2,100


Cost of revenues



1,880




1,474


Gross profit



762




626


Research and development expenses



6,557




5,137


Sales and marketing expenses



3,669




3,061


General and administrative expenses



3,527




3,306


Operating loss



12,991




10,878


Finance expenses (income), net



4




(67)











Net loss and comprehensive loss



12,995




10,811


Basic and diluted net loss per share



3.57




5.4


Weighted average number of shares outstanding used in
computing basic and diluted loss per share



3,637,322




2,018,573


 

ICECURE MEDICAL LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




Nine months ended
September 30,




2026



2025





U.S. dollars in
thousands


Cash flows from operating activities
















Net loss


(12,995)



(10,811)



Adjustments to reconcile net loss to net cash used in operating activities:










Depreciation



207




224



Share-based compensation



687




1,102



Exchange rate changes in cash and cash equivalents and long-term restricted
deposits



(24)




 

118



Other finance cost



-




(34)



Changes in assets and liabilities:










Decrease (increase) in trade receivables



(60)




117



Decrease (increase) in prepaid expenses and other receivables



(546)




145



Decrease (increase) in inventory



47




(723)



Decrease in right of use assets



228




251



Increase (decrease) in trade payables



208




(81)



Decrease in lease liabilities



(227)




(212)



Increase in employees and employees related liabilities



365




595



Decrease in other current liabilities



(465)




(246)



Net cash used in operating activities



(12,575)




(9,555)













Cash flows from investing activities










Investment in short-term deposits



-




(5,000)



Purchase of property and equipment



(154)




(31)



Net cash used in investing activities



(154)




(5,031)













Cash flows from financing activities:










Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net
of issuance costs



12,020




12,114



Proceeds from exercise of warrants and pre-funded warrants



10




-



Net cash provided by financing activities



12,030




12,114













Decrease in cash and cash equivalents



(699)




(2,472)



Cash and cash equivalents at beginning of the year



8,897




7,564



Effect of exchange rate fluctuations on balances of cash and cash equivalents



22




(121)



Cash and cash equivalents at end of period



8,220




4,971













Non-cash activities










Obtaining a right-of-use asset in exchange for a lease liability



718




41



 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-reports-financial--operational-results-for-the-nine-months-ended-september-30-2026-83-year-over-year-growth-in-us-sales-and-major-growth-in-us-commercial-reach-to-21-states-302943738.html

SOURCE IceCure Medical

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did IceCure Medical’s U.S. sales grow in the first nine months of 2026?

U.S. sales of ProSense and its cryoprobes rose 83% year over year in the first nine months of 2026.

Where did IceCure Medical enroll its first ChoICE study patients?

The first two ChoICE study patients enrolled at West Cancer Center in Tennessee and Adventist Health Glendale in California after the third quarter of 2026.

Why did IceCure Medical’s research and development spending rise in the first nine months of 2026?

IceCure Medical attributed the increase mainly to higher spending on the ChoICE study and other clinical and development activities.

What did the Society of Interventional Oncology request about cryoablation in IceCure Medical’s Q3 update?

The Society of Interventional Oncology petitioned the National Comprehensive Cancer Network to add cryoablation performed through the skin as a breast cancer treatment option in its guidelines.

Keep reading